Aktienanalyse zu Korro Bio Inc (KRRO)KRROKorro Bio Inc

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Korro Bio Inc is a good buy right now due to its current price of $15.85, which is significantly below analyst price targets of $20 and $23. The stock has shown a strong upward momentum with a 5-day change of +31.82% and a year-to-date change of +96.83%. However, the main risk is its negative earnings, with an EPS of -1.69 reported for the last quarter and a projected EPS of -1.14 for the next earnings date.